2 weeks ago
9
Soumya Eswaran
Wed, December 3, 2025 astatine 6:25 AM CST 3 min read
Meridian Funds, managed by ArrowMark Partners, released its third-quarter 2025 capitalist missive for the “Meridian Small Cap Growth Fund.” A transcript of the missive tin beryllium downloaded here. Driven by continued gains successful exertion and falling enslaved yields, equities reached grounds highs successful the quarter. U.S. tiny caps outperformed successful the quarter, gaining 12.4%, portion ample caps returned 5.3%. Among tiny caps, worth stocks somewhat surpassed maturation stocks, returning 12.6% and 12.2%, respectively, according to Russell indices. In this environment, the money returned 4.20% (net) successful the 3rd 4th compared to the Russell 2000 Growth Index’s 12.19% return. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.
In its third-quarter 2025 capitalist letter, Meridian Small Cap Growth Fund highlighted stocks specified arsenic Zenas BioPharma, Inc. (NASDAQ:ZBIO). Zenas BioPharma, Inc. (NASDAQ:ZBIO) is simply a clinical-stage biopharmaceutical company. The one-month instrumentality of Zenas BioPharma, Inc. (NASDAQ:ZBIO) was 13.00%, and its shares gained 250.61% of their worth implicit the past 52 weeks. On December 02, 2025, Zenas BioPharma, Inc. (NASDAQ:ZBIO) banal closed astatine $34.50 per share, with a marketplace capitalization of $1.852 billion.
Meridian Small Cap Growth Fund stated the pursuing regarding Zenas BioPharma, Inc. (NASDAQ:ZBIO) successful its 3rd 4th 2025 capitalist letter:
"Zenas BioPharma, Inc. (NASDAQ:ZBIO) is simply a clinical-stage planetary biopharmaceutical institution focused connected processing transformative therapies for patients with autoimmune diseases. Its pb drug, Obexelimab, is successful Phase 3 objective trials and, portion results are inactive pending, appears connected way for imaginable support and motorboat successful 2027. The banal performed good amid a broadly improving biotechnology environment, and the institution announced an statement with Royalty Pharma for up to $300 cardinal successful non-dilutive financing. This superior infusion is expected to enactment completion of the objective proceedings and the consequent motorboat and commercialization of Obexelimab. During the quarter, we trimmed our presumption arsenic the stock terms appreciated, accordant with our disciplined valuation approach."
Zenas BioPharma, Inc. (NASDAQ:ZBIO) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 13 hedge money portfolios held Zenas BioPharma, Inc. (NASDAQ:ZBIO) astatine the extremity of the 3rd quarter, the aforesaid arsenic successful the erstwhile quarter. While we admit the imaginable of Zenas BioPharma, Inc. (NASDAQ:ZBIO) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
English (CA) · 
English (US) · 
Spanish (MX) ·